Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys, Gene Logic, Nonlinear Dynamics, Ingenuity, Scali, ACD/Labs


Nasdaq Grants Accelrys Filing Extension for Quarterly Report

The Nasdaq exchange has granted Accelrys an extension to file its quarterly report for the period ended Dec. 31, 2005, the company said this week.

The filing has been delayed because Accelrys is restating its quarterly financial statements from Jan. 1, 2000, to Sept. 30, 2005 [BioInform 12-26-05].

In Februray, Nasdaq issued Accelrys a noncompliance notice because it had not yet filed its financial statements for its third fiscal quarter [BioInform 02-24-06].

On Monday, Nasdaq extended the filing date to May 31. Accelrys stated that it expects to complete its quarterly report as well as its restated historical financial statements by that time.

Gene Logic's Q1 Revenues Fall 35 Percent as Net Losses More than Double

Gene Logic this week reported a 35-percent drop in first-quarter revenues amid widened net losses.

For the quarter ended March 31, Gene Logic's total revenue fell to $12.8 million from $19.7 million in the first quarter of 2005. Revenues fell across all three of the firm's operating divisions: Genomics Division revenue declined to $8.7 million from 13.2 million in the prior-year period; Preclinical revenue fell to $4 million from $6.4 million in the prior-year period; and Drug Repositioning revenue dropped to $20,000 from $67,000 in the same period of 2005.

Gene Logic said in a statement that the results were in line with expectations and that the Genomics Division has been "transitioning" over the past five quarters from a model based on database subscriptions and a few large customers to one with multiple sources of revenue — including revenues "from perpetual licenses and microarray data generation and analysis services" — and a broader customer base. The company added that the division's results are likely to be "variable," however, "when certain opportunities fail to materialize or are deferred."

The results for the Genomics Division in the first quarter reflect "lower sales due to the non-signing of a previously anticipated perpetual license and the deferral of several opportunities until later in the year," the company said.

Gene Logic's net losses ballooned to $11.8 million, nearly three times the company's net loss of $4.1 million in the first quarter of 2005. The company attributed the widening losses to the revenue shortfall in the Genomics Division.

R&D spending increased to $2.4 million from $1.5 million in the first quarter of 2005.

Gene Logic had $28.4 million in cash and cash equivalents as of March 31, and $63.9 million in cash, cash equivalents, and marketable securities available for sale.

Hoefer to Distribute Nonlinear Dynamics Software with Imaging Systems …

Nonlinear Dynamics said this week that it has entered into a worldwide distribution agreement with Harvard Bioscience subsidiary Hoefer, a supplier of gel electrophoresis equipment.

Under the terms of the agreement, Hoefer will supply Nonlinear's TotalLab 1D image analysis software with its ULTima range of imaging systems.

Specifidally, Nonlinear's "entry-level" TL100 1D gel analysis software will be included with all ULTima systems.

… As APAF Upgrades Progenesis Installation

Nonlinear Dynamics said this week that the Australian Proteome Analysis Facility has adopted its SameSpots 2D gel image analysis method by investing the company's TT900 S2S technology to its installed Progenesis PG240 software system.

Mark Baker, CEO of the Australian Proteome Analysis Facility, said in a statement that TT900 S2S with SameSpots offers "significant improvements in image matching."

Financial terms of the license were not disclosed.

Boehringer Ingelheim Takes Global License to Ingenuity's IPA

Ingenuity Systems said this week that Boehringer Ingelheim has taken a global access to its Ingenuity Pathways Analysis software.

Boehringer Ingelheim researchers at all sites will have access to IPA.

Financial terms of the agreement were not disclosed.

IBCP Deploys Scali Cluster-Management System

France's Institute for the Biology and Chemistry of Proteins, a research organization administered jointly by France's National Council for Scientific Research and Lyon University, is using the Scali Manage 5 cluster-management system from Scali, the company said this week.

IBCP uses an 11-node Dell cluster to analyze and predict protein sequence, structure, and function and to study the response of viruses to drugs.

The cluster includes 11 Dell Power Edge 2650 servers as compute nodes, 2 Dell Power Edge 2850 file servers attached to a DELL EMC CX400 SAN storage system, an NEC 120 Rf-1 server attached to an NEC ST 1430 storage system, a 120 Rf-1 web server, and an NEC 120-Rh2 server running the Scali Manage configuration server and a PBSPro server.

Scynexis Expands License to ACD/Labs NMR Software

Advanced Chemistry Development said this week that drug discovery firm Scynexis has expanded its installation of ACD/1D NMR Processor, at its Research Triangle Park, NC, research facility.

ACD/1D NMR Processor supports all major NMR formats and includes J-Coupler, a multiplet analysis tool for efficiently gathering spectral features.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.